---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-049116"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:05:13.736625+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Madrigal reports Q4 2023 cash of $634M, appoints new CFO, resmetirom PDUFA March 14

## Summary
- Appointed Mardi C. Dier as CFO; previously CFO at Portola, Ultragenyx, and Acelyrin.
- Resmetirom PDUFA date March 14, 2024; company anticipates first NASH approval.
- Cash and marketable securities $634.1M at Dec 31, 2023, up from $358.8M at Dec 31, 2022.
- Operating expenses Q4 2023 $117.2M vs $85.3M YoY; full year $380.5M vs $293.6M.
- G&A expenses Q4 2023 $46.5M vs $14.6M YoY due to commercial launch preparation.

## SEC filing metadata
- accession: 0001193125-24-049116
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312524049116/0001193125-24-049116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312524049116/d743882d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-049116
- JSON: https://secwatch.observer/filing/0001193125-24-049116.json
- Plain text: https://secwatch.observer/filing/0001193125-24-049116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.